Broadcom Inc. (AVGO)
Verdict history · AVGO
Every call Verdix has made on AVGO.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
Click any date below to read that write-up
Since August, the stock has dropped 6.2% from $393 to $368, landing exactly on the 61.8% Fibonacci retracement — a level that separated the prior panel's WAIT from the current low-conviction BUY. The addition of two new voices who see the dip as a Dhandho mispricing rather than a broken thesis tips the balance: the business quality is undisputed, all three holdouts object only to price and timing, and no one is actually bearish on the story itself.
See methodology for how verdicts are produced. Full track record →
The panel’s case for AVGO — and where they disagree.
The case for outweighs the case against at today's price.
NASDAQ · Information Technology / Semiconductors & Infrastructure Software · 2026-08-22 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
BuyLOW confidence
Why
Six distinct analytical frameworks agree Broadcom's AI chip-and-software franchise carries a wide moat and generates $27B in annual free cash flow, but split 3-3 on whether the current price of $368 already discounts a near-doubling of revenue that may prove too heroic. The panel lands at a low-conviction BUY: the bull case is intact, no one is bearish on the business itself, and even the cautious voices concede they are arguing about entry timing.Level to watch
Key support 366.56−0.5% from 368.45
Next catalyst
Trigger to confirm the correction is over: A weekly close above the EMA20 (~$385) on volume would signal the 61.8% Fibonacci retracement has held and the Stage 2 uptrend is resuming.The panel's take
Verdict: BUY · Conviction: LOW · Last price: 368.45 · Changed from WAIT
Panel: 3 Bullish · 3 Neutral · 0 Bearish → BUY
What changed since 2026-08-15:
- Price: 392.99 → 368.45 (-6.24%)
- Panel: 1 of 6 → 3 of 6 now Bullish — composition also changed: added The Asymmetric Bargainer, The Disruptive-Innovation Seeker; removed The Macro Opportunist, The Scuttlebutt Growth Investor
- Trigger: A weekly close below the EMA50 ($355) would shift the trend from Stage 2 correction to Stage 3 distribution, invalidating the structural bull case and flipping the verdict to SELL or WAIT.
- Verdict: WAIT → BUY
Since August, the stock has dropped 6.2% from $393 to $368, landing exactly on the 61.8% Fibonacci retracement — a level that separated the prior panel's WAIT from the current low-conviction BUY. The addition of two new voices who see the dip as a Dhandho mispricing rather than a broken thesis tips the balance: the business quality is undisputed, all three holdouts object only to price and timing, and no one is actually bearish on the story itself.
Three of six voices back BUY on a business with a very wide moat, 37% ROE, and a forward PEG below 0.5 — and even the three holdouts concede the business quality, objecting only on price and timing and wanting a deeper pullback before committing. With zero bearish votes and the stock sitting at the make-or-break 61.8% Fibonacci retracement, the arithmetic tilts to BUY at low confidence: the bull case is intact but the entry is early by the cautious voices' own standards.
Key levels
Key levels · AVGO
USD · as of 2026-08-22Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key support at $366.56 is the weekly 61.8% Fibonacci retracement of the $495–$287.17 swing — price is testing it now, and a sustained hold for two or more weekly closes would signal the correction base is firming. Key support at $355.14 is the weekly EMA50, the line between a Stage 2 correction and Stage 3 distribution that every cautious voice on the panel flagged as make-or-break. Key resistance in the $386–$388 zone bands the weekly EMA20 ($384.51) with the monthly 23.6% Fibonacci retracement ($387.98); reclaiming it on rising volume would confirm the correction is over. The all-time high at $495 is the historical resistance zone that rejected price on the last three rally attempts. The analyst consensus target of $526 sits 43% above the current price.
What legendary investors think
We ran Broadcom Inc. past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMed
Signal: DCF-based value of $390–$420 sits modestly above the current price, but the real concern is that the FY2027 consensus revenue of $172B embeds a near-doubling from FY2025 that assumes perfect AI-spending acceleration, no competitive disruption, and flawless VMware integration, a heroic set of assumptions my 9.5% WACC already penalizes. Conviction: Conviction is held back because the value gap of 6–14% is narrow relative to the $52B net-debt overhang and the wide dispersion between bear-case $290 and bull-case $520.
The GARP OperatorGrowth (GARP)🟢 BullishMed
Signal: A forward P/E of 21 against 60%-plus EPS growth delivers a PEG ratio of 0.36, a level that on any historical screen would flag this as deeply undervalued for a Fast Grower with $27B in free cash flow and a $110B backlog. Conviction: Confidence runs high because the PEG, the cash-flow coverage of debt in under two years, and four consecutive earnings beats are three independent facts that all point the same direction.
The Moat CompounderValue/Quality/Moat⚫ NeutralMed
Signal: A 37% ROE, 39% net profit margin, and 76% gross margin on the software side signal a very wide moat built on switching costs that make hyperscaler custom-chip relationships and VMware enterprise contracts extraordinarily sticky. This is exactly the kind of business quality I look for. Conviction: The reservation stems from a 63-to-1 insider sell-to-buy ratio over the last 90 days; when the captain and crew are selling lifeboats, I cannot ignore the signal even when the business itself looks first-class.
The Asymmetric BargainerContrarian/Deep Value🟢 BullishMed
Signal: Passing all four Dhandho tests, the setup offers a downside capped at roughly 15–20% (to ~$295) against an analyst consensus target of $526 implying 43% upside, with the $27B free-cash-flow stream providing a resilient floor under any AI-slowdown scenario. Conviction: The conviction strengthens because the gap between market-perceived uncertainty about AI capex cyclicality and the reality of multi-year hyperscaler contracts creates a classic mispricing arbitrage.
The Forensic SkepticContrarian/Forensic⚫ NeutralLow
Signal: Negative tangible book value of $10.18 per share, with $97.8B in goodwill representing 123% of total equity, means the balance sheet is propped up entirely by acquisition accounting; there is no hard-asset cushion if the VMware thesis falters. Conviction: My low confidence reflects the 33-out-of-42 Strong Buy consensus: when the crowd is this aligned and insiders are selling at a 64-to-1 dollar ratio, the asymmetry is against the bulls.
The Disruptive-Innovation SeekerDisruptive Innovation🟢 BullishMed
Signal: Broadcom's custom ASICs and networking silicon sit at the intersection of the AI infrastructure buildout and the enterprise software transformation, with a $110B backlog confirming demand that is still in the early-majority phase of the S-curve, where annual growth can compound at 30–40% for half a decade. Conviction: Conviction stays measured because customer concentration among a handful of hyperscalers means a single in-house chip-design announcement from Google or Meta could compress the multiple overnight, however unlikely that looks today.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All six voices agree the business itself is exceptional: a wide moat anchored by switching costs in custom AI accelerators and VMware's enterprise-software annuity, with a 37% ROE and $27B in annual free cash flow that covers the $52B net-debt load in under two years.
- The forward P/E of roughly 21 and PEG ratio below 0.5 make the stock appear cheap on a growth-adjusted basis; no one disputes the arithmetic, only whether the growth rate backing those numbers is sustainable.
- Insider selling is the panel's shared concern: $24M in sales versus $374K in purchases over 90 days registers with every archetype, from yellow flag to red flag depending on the framework.
- The 61.8% Fibonacci retracement near $366 is recognized as the make-or-break technical level; a hold confirms the correction, a break shifts the structure.
The real debate
- The GARP Operator and the Asymmetric Bargainer treat the PEG of 0.36 as a screaming-buy signal anchored by multi-year hyperscaler contracts, while the Forensic Skeptic argues that PEG is a mirage because the FY2027 EPS of $19.42 requires Broadcom to add roughly an AMD's worth of annual revenue in a single year.
- The Disruptive-Innovation Seeker dismisses the 26% pullback from the all-time high as short-term noise against a 5-year S-curve, while the Moat Compounder sees bearish weekly and monthly MACD readings and wants a wider margin of safety before committing capital.
- The Intrinsic-Value Modeler's DCF yields only 6–14% upside after penalizing the heroic consensus assumptions, which the Asymmetric Bargainer views as overly conservative: the Dhandho framework says the downside is naturally capped by $27B in annual FCF regardless of what the discount rate says.
The question it comes down to: Can Broadcom's AI-driven revenue actually double in two years as consensus requires, or will the law of large numbers and hyperscaler in-house chip efforts make the PEG of 0.36 a mirage?
The bottom line
- Trigger to confirm the correction is over: A weekly close above the EMA20 (~$385) on volume would signal the 61.8% Fibonacci retracement has held and the Stage 2 uptrend is resuming.
- Risk to monitor: A weekly close below the EMA50 (~$355) would shift the structure from Stage 2 correction to Stage 3 distribution, invalidating the structural bull case.
- Next catalyst: Q2 FY2026 earnings on September 2: the magnitude of the beat and FY2027 guidance will either validate or undermine the consensus $172B revenue estimate that underpins every bull case on this panel.
- Key number to watch: FY2027 EPS of $19.42 is the linchpin of the forward-PEG thesis; any guidance implying a figure below $15 would snap the PEG above 1.0 and erase the growth-adjusted discount.
- Further out: A hyperscaler announcing in-house chip development at scale would threaten Broadcom's custom-ASIC franchise directly, compressing the multiple regardless of VMware execution.
contact@verdixhq.com · Published 2026-08-22 · Prices as of 2026-08-22 · Time horizon: 3–12 months · No direct position held in AVGO · AVGO verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated